PubRank

John Hiscott

Author PubWeight™ 140.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Triggering the interferon antiviral response through an IKK-related pathway. Science 2003 11.62
2 VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003 5.89
3 Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol 2002 4.31
4 A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005 3.59
5 The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat Immunol 2007 2.91
6 Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA. J Biol Chem 2003 2.57
7 RIG-I-like receptors: sensing and responding to RNA virus infection. Semin Immunol 2009 2.47
8 The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 2002 2.33
9 Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J Biol Chem 2005 2.27
10 Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. J Virol 2006 2.15
11 Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity. J Virol 2004 2.06
12 Recognition of the measles virus nucleocapsid as a mechanism of IRF-3 activation. J Virol 2002 2.04
13 Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 2005 1.97
14 Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell Host Microbe 2012 1.93
15 Retinoic acid-inducible gene-I and interferon-beta promoter stimulator-1 augment proapoptotic responses following mammalian reovirus infection via interferon regulatory factor-3. J Biol Chem 2007 1.81
16 Multiple signaling pathways leading to the activation of interferon regulatory factor 3. Biochem Pharmacol 2002 1.79
17 Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression. J Virol 2006 1.75
18 Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A 2008 1.73
19 Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol 2005 1.72
20 The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation. PLoS Pathog 2009 1.57
21 TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003 1.57
22 Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon. J Immunol 2006 1.56
23 RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol 2010 1.55
24 Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008 1.50
25 Ubiquitin-regulated recruitment of IkappaB kinase epsilon to the MAVS interferon signaling adapter. Mol Cell Biol 2009 1.49
26 Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr Opin Immunol 2011 1.46
27 The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy. Immunity 2012 1.44
28 A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 2010 1.38
29 Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res 2006 1.25
30 A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells. J Biol Chem 2007 1.23
31 Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology 2002 1.22
32 Retinoic acid inducible gene-I and mda-5 are involved in influenza A virus-induced expression of antiviral cytokines. Microbes Infect 2006 1.22
33 Involvement of the IkappaB kinase (IKK)-related kinases tank-binding kinase 1/IKKi and cullin-based ubiquitin ligases in IFN regulatory factor-3 degradation. J Immunol 2006 1.19
34 A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response. Cell Res 2011 1.18
35 A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization. J Biol Chem 2004 1.12
36 Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7. Eur J Immunol 2009 1.12
37 Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS. J Biol Chem 2009 1.11
38 Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription. J Mol Biol 2002 1.09
39 Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res 2004 1.09
40 VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol Ther 2010 1.08
41 Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virol J 2006 1.08
42 Multiple NF-kappaB and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells. J Immunol 2007 1.07
43 Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog 2013 1.07
44 Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J Virol 2006 1.06
45 Involvement of TBK1 and IKKepsilon in lipopolysaccharide-induced activation of the interferon response in primary human macrophages. Eur J Immunol 2007 1.05
46 Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. J Immunol 2002 1.04
47 Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe 2013 1.03
48 Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. J Virol 2014 1.03
49 Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol 2009 1.03
50 Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol 2005 1.03
51 Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 2008 1.02
52 HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog 2010 1.01
53 A requirement for NF-kappaB induction in the production of replication-competent HHV-8 virions. Oncogene 2004 1.01
54 Ub surprised: viral ovarian tumor domain proteases remove ubiquitin and ISG15 conjugates. Cell Host Microbe 2007 0.99
55 Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 2007 0.98
56 Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. Virology 2007 0.97
57 Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol 2006 0.97
58 On the TRAIL to apoptosis. Cytokine Growth Factor Rev 2002 0.97
59 In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res 2002 0.96
60 Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy. J Virol 2013 0.95
61 Suppression of IRF4 by IRF1, 3, and 7 in Noxa expression is a necessary event for IFN-γ-mediated tumor elimination. Mol Cancer Res 2011 0.94
62 Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 2008 0.93
63 STING-ing the antiviral pathway. J Mol Cell Biol 2009 0.93
64 The interface between the innate interferon response and expression of host retroviral restriction factors. Cytokine 2010 0.90
65 Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. Oncogene 2002 0.89
66 Gene expression profiling of the host response to HIV-1 B, C, or A/E infection in monocyte-derived dendritic cells. Virology 2006 0.89
67 IRF-4 activities in HTLV-I-induced T cell leukemogenesis. J Interferon Cytokine Res 2002 0.89
68 The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell Microbiol 2009 0.89
69 IFN regulatory factor 4 participates in the human T cell lymphotropic virus type I-mediated activation of the IL-15 receptor alpha promoter. J Immunol 2002 0.88
70 SAMHD1 host restriction factor: a link with innate immune sensing of retrovirus infection. J Mol Biol 2013 0.88
71 HCV NS5A and IRF9 compete for CypA binding. J Hepatol 2012 0.88
72 Functional analysis of a dominant negative mutation of interferon regulatory factor 5. PLoS One 2009 0.88
73 Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells. Cytokine Growth Factor Rev 2010 0.88
74 Cell-specific regulation of TRBP1 promoter by NF-Y transcription factor in lymphocytes and astrocytes. J Mol Biol 2005 0.87
75 Promoter organization of the interferon-A genes differentially affects virus-induced expression and responsiveness to TBK1 and IKKepsilon. J Biol Chem 2005 0.87
76 Innate immune sensing of HIV-1 infection. Curr Opin HIV AIDS 2015 0.87
77 Additive activity between the trans-activation response RNA-binding protein, TRBP2, and cyclin T1 on HIV type 1 expression and viral production in murine cells. AIDS Res Hum Retroviruses 2003 0.86
78 Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine 2003 0.86
79 Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene 2003 0.86
80 The use of oncolytic viruses to overcome lung cancer drug resistance. Curr Opin Virol 2012 0.86
81 Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis. Cytokine Growth Factor Rev 2011 0.85
82 MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR. FASEB J 2010 0.85
83 Tom70 imports antiviral immunity to the mitochondria. Cell Res 2010 0.84
84 Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol 2011 0.84
85 Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res 2005 0.84
86 Another detour on the Toll road to the interferon antiviral response. Nat Struct Mol Biol 2004 0.82
87 Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude. Hepatology 2014 0.82
88 IκB kinase ε targets interferon regulatory factor 1 in activated T lymphocytes. Mol Cell Biol 2014 0.81
89 IκB kinase ε-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis. J Virol 2011 0.81
90 BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis. Mol Ther 2013 0.80
91 Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Mol Ther 2013 0.80
92 Leukotriene A4 hydrolase expression in PEL cells is regulated at the transcriptional level and leads to increased leukotriene B4 production. J Immunol 2006 0.80
93 Intact type I Interferon production and IRF7 function in sooty mangabeys. PLoS Pathog 2013 0.80
94 Differential regulation of human papillomavirus type 8 by interferon regulatory factors 3 and 7. J Virol 2010 0.80
95 Regulation of arginase II by interferon regulatory factor 3 and the involvement of polyamines in the antiviral response. FEBS J 2005 0.80
96 Anti-viral tetris: modulation of the innate anti-viral immune response by A20. Adv Exp Med Biol 2014 0.78
97 Regulatory studies of murine methylenetetrahydrofolate reductase reveal two major promoters and NF-kappaB sensitivity. Biochim Biophys Acta 2005 0.78
98 Cytokines. Curr Opin Immunol 2011 0.78
99 CuRTAiling interferon regulatory factor signaling with the E3 ligase RAUL. Immunity 2010 0.77
100 RIG-I has guts: identification of a role for RIG-I in colitis development. Cell Res 2007 0.77
101 Recruitment of histone deacetylase 3 to the interferon-A gene promoters attenuates interferon expression. PLoS One 2012 0.77
102 IRF-3 releases its inhibitions. Structure 2005 0.76
103 Repression of DNA repair mechanisms in IRF-4-expressing and HTLV-I-infected T lymphocytes. J Interferon Cytokine Res 2005 0.76
104 The intersection between viral oncolysis, drug resistance, and autophagy. Biol Chem 2015 0.75
105 Conference highlights of the 16th International Conference on Human Retrovirology: HTLV and related retroviruses, 26-30 June 2013, Montreal, Canada. Retrovirology 2014 0.75
106 Breaking the barrier: membrane fusion triggers innate antiviral immunity. Nat Immunol 2012 0.75
107 Uncoating reo: uncovering the steps critical for oncolysis. Mol Ther 2007 0.75
108 RAIDD Mediates TLR3 and IRF7 Driven Type I Interferon Production. Cell Physiol Biochem 2016 0.75
109 Cytokine networks during HIV infection: shifting the balance. Cytokine Growth Factor Rev 2012 0.75